

# Giuseppe Saglio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2896067/publications.pdf>

Version: 2024-02-01

586  
papers

48,759  
citations

3721

89  
h-index

1928

207  
g-index

598  
all docs

598  
docs citations

598  
times ranked

22068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
2	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
3	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2002, 346, 645-652.	13.9	1,899
4	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
5	Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. <i>New England Journal of Medicine</i> , 2005, 352, 254-266.	13.9	1,637
6	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2251-2259.	13.9	1,497
7	Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia " A Europe Against Cancer Program. <i>Leukemia</i> , 2003, 17, 2318-2357.	3.3	1,359
8	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
9	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
10	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
11	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. <i>Leukemia</i> , 1999, 13, 1901-1928.	3.3	1,038
12	European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 966-984.	3.3	875
13	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) " a Europe against cancer program. <i>Leukemia</i> , 2003, 17, 2474-2486.	3.3	806
14	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2333-2340.	0.8	724
15	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. <i>Leukemia</i> , 2016, 30, 1044-1054.	3.3	685
16	PML targeting eradicates quiescent leukaemia-initiating cells. <i>Nature</i> , 2008, 453, 1072-1078.	13.7	517
17	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , 2011, 118, 1208-1215.	0.6	486
18	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 7374-7379.	3.2	475

#	ARTICLE	IF	CITATIONS
19	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology</i> , The, 2011, 12, 841-851.	5.1	444
20	Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5195-5201.	0.8	409
21	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	0.6	400
22	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. <i>Leukemia</i> , 2012, 26, 2197-2203.	3.3	395
23	Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. <i>Blood</i> , 1997, 90, 1014-21.	0.6	375
24	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	0.6	364
25	Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL) Tj ETQq1 1 0.784314 rgBT/Overbo 0.6 357	0.6	357
26	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4100-4109.	0.8	350
27	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , 2008, 112, 3330-3338.	0.6	350
28	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	0.6	344
29	Standardized definitions of molecular response in chronic myeloid leukemia. <i>Leukemia</i> , 2012, 26, 2172-2175.	3.3	339
30	Chronic myeloid leukemia and interferon- $\gamma$ : a study of complete cytogenetic responders. <i>Blood</i> , 2001, 98, 3074-3081.	0.6	309
31	Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Journal of Clinical Oncology</i> , 2009, 27, 4204-4210.	0.8	292
32	Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. <i>British Journal of Haematology</i> , 1988, 69, 359-366.	1.2	291
33	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	0.6	284
34	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 999-1003.	3.3	280
35	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. <i>Leukemia</i> , 2006, 20, 1103-1108.	3.3	278
36	<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i> Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	0.8	276

#	ARTICLE	IF	CITATIONS
37	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RAR $\pm$ Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter "AIDA" Trial. <i>Blood</i> , 1998, 92, 784-789.	0.6	266
38	Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. <i>Leukemia</i> , 2017, 31, 1525-1531.	3.3	232
39	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014, 123, 1353-1360.	0.6	231
40	Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. <i>Leukemia</i> , 2002, 16, 2115-2121.	3.3	219
41	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. <i>Leukemia</i> , 2013, 27, 107-112.	3.3	212
42	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. <i>European Journal of Haematology</i> , 2008, 80, 168-176.	1.1	210
43	Molecular Pathways: BCR-ABL. <i>Clinical Cancer Research</i> , 2012, 18, 930-937.	3.2	208
44	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938.	0.6	203
45	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
46	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR $\alpha$ -positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007, 92, 1173-1179.	1.7	198
47	Harmonization of molecular monitoring of CML therapy in Europe. <i>Leukemia</i> , 2009, 23, 1957-1963.	3.3	196
48	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR $\alpha$ -positive chronic eosinophilic leukemia. <i>Blood</i> , 2007, 109, 4635-4640.	0.6	195
49	Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. <i>Leukemia</i> , 2013, 27, 1310-1315.	3.3	193
50	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , 1996, 94, 533-543.	1.2	187
51	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. <i>Leukemia</i> , 2006, 20, 1925-1930.	3.3	184
52	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , 1993, 81, 166-176.	0.6	182
53	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006, 108, 1999-2005.	0.6	181
54	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	0.6	178

#	ARTICLE	IF	CITATIONS
55	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	0.6	173
56	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007, 92, 401-404.	1.7	172
57	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , 1993, 81, 166-176.	0.6	170
58	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , 2014, 123, 2317-2324.	0.6	167
59	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	3.3	159
60	A randomized study of interferon- $\alpha$ versus interferon- $\alpha$ and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002, 99, 1527-1535.	0.6	158
61	Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. <i>Blood</i> , 2000, 95, 651-9.	0.6	152
62	Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2003, 21, 1988-1995.	0.8	145
63	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180034. <i>American Journal of Hematology</i> , 2016, 91, 869-874.	2.0	145
64	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , 1990, 76, 1819-1824.	0.6	141
65	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010, 116, e111-e117.	0.6	141
66	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 1543-1556.	3.3	127
67	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 945-954.	1.2	124
68	Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib. <i>Clinical Chemistry</i> , 2004, 50, 1205-1213.	1.5	120
69	Cloning and Gene Mapping of the Chromosome 13q14 Region Deleted in Chronic Lymphocytic Leukemia. <i>Genomics</i> , 1997, 42, 369-377.	1.3	119
70	Deferasirox is a powerful NF- $\kappa$ B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. <i>Haematologica</i> , 2010, 95, 1308-1316.	1.7	118
71	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. <i>Cancer</i> , 2010, 116, 3852-3861.	2.0	115
72	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115

#	ARTICLE	IF	CITATIONS
73	Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine ? threonine at position 75 (E 19) of the ? chain. <i>Human Genetics</i> , 1976, 32, 305-313.	1.8	110
74	Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. <i>Blood</i> , 1996, 87, 1075-1080.	0.6	110
75	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
76	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	0.6	109
77	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , 2015, 125, 2771-2778.	0.6	102
78	Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. <i>Leukemia</i> , 2008, 22, 96-102.	3.3	100
79	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. <i>Haematologica</i> , 2008, 93, 921-924.	1.7	100
80	Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. <i>Leukemia and Lymphoma</i> , 2011, 52, 896-904.	0.6	100
81	Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. <i>Cancer</i> , 2005, 104, 101-109.	2.0	99
82	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , 2008, 112, 3847-3855.	0.6	99
83	Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. <i>Leukemia</i> , 2002, 16, 1176-1181.	3.3	98
84	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1721-1726.	1.2	98
85	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	0.6	98
86	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia.. <i>EMBO Journal</i> , 1984, 3, 2641-2645.	3.5	97
87	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97
88	Imatinib and pegylated human recombinant interferon- $\beta$ 2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 104, 4245-4251.	0.6	96
89	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , 2013, 98, 193-200.	1.7	96
90	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. <i>PLoS ONE</i> , 2016, 11, e0162866.	1.1	96

#	ARTICLE	IF	CITATIONS
91	Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis. <i>Acta Haematologica</i> , 2008, 120, 70-74.	0.7	95
92	WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2004, 112, 79-84.	0.7	94
93	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016, 101, 541-558.	1.7	92
94	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796.	1.7	91
95	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013, 121, 3703-3708.	0.6	91
96	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. <i>Leukemia</i> , 2016, 30, 57-64.	3.3	91
97	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	3.2	90
98	Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. <i>Journal of Clinical Oncology</i> , 2012, 30, 4323-4329.	0.8	90
99	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2351-2361.	0.6	90
100	Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982, 79, 2347-2351.	3.3	89
101	Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis. , 1999, 24, 16-23.		89
102	Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients. <i>Annals of Oncology</i> , 1998, 9, 55-61.	0.6	88
103	Monitoring treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2008, 93, 161-169.	1.7	88
104	The NF- $\kappa$ B pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. <i>Leukemia</i> , 2006, 20, 61-67.	3.3	87
105	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 723-733.	0.8	86
106	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2005, 19, 628-635.	3.3	85
107	Nuclear factor $\kappa$ B as a target for new drug development in myeloid malignancies. <i>Haematologica</i> , 2007, 92, 1224-1229.	1.7	84
108	What are RBC-transfusion-dependence and -independence?. <i>Leukemia Research</i> , 2011, 35, 8-11.	0.4	84

#	ARTICLE	IF	CITATIONS
109	Distribution of Kaposi's sarcoma herpesvirus sequences among lymphoid malignancies in Italy and Spain. <i>British Journal of Haematology</i> , 1995, 91, 918-920.	1.2	81
110	AIDS-Related Burkitt's Lymphoma: Morphologic and Immunophenotypic Study of Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 1995, 103, 561-567.	0.4	78
111	Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. <i>Aids</i> , 1996, 10, 941-949.	1.0	78
112	Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2009, 82, 61-68.	1.1	78
113	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	3.3	77
114	c-erbB-2 and andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. <i>International Journal of Cancer</i> , 1991, 47, 833-838.	2.3	76
115	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 439-442.	1.7	74
116	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	1.7	73
117	Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	2.0	72
118	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
119	A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: Possible involvement in the genesis of the Philadelphia chromosome translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9882-9887.	3.3	71
120	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71
121	GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. <i>Blood</i> , 1998, 91, 2334-2340.	0.6	70
122	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 2284-2290.	0.6	69
123	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. <i>Blood</i> , 2012, 119, 5963-5971.	0.6	69
124	Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. <i>Cancer Genetics and Cytogenetics</i> , 1992, 64, 170-173.	1.0	68
125	G $\beta$ 3 and A $\beta$ 3 globin chains separation and quantitation by isoelectric focusing. <i>Biochemical and Biophysical Research Communications</i> , 1979, 87, 1-8.	1.0	67
126	BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. <i>Leukemia</i> , 2014, 28, 1326-1333.	3.3	67



#	ARTICLE	IF	CITATIONS
127	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 2723-2735.	2.5	67
128	Neutrophilic-chronic myeloid leukemia. <i>Cancer</i> , 2002, 94, 2416-2425.	2.0	66
129	Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2- $\hat{1}\pm$ and Tfr2- $\hat{1}^2$ isoforms in different tissues. <i>Blood</i> , 2010, 115, 3382-3389.	0.6	66
130	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 59, 109-116.	1.4	66
131	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
132	False-positive results with PCR to detect leukaemia-specific transcript. <i>Lancet, The</i> , 1990, 335, 1037-1038.	6.3	65
133	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003, 120, 484-487.	1.2	63
134	Expert opinion on management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020, 34, 1495-1502.	3.3	63
135	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, e51-e52.	0.8	61
136	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
137	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. <i>Oncotarget</i> , 2017, 8, 35508-35522.	0.8	61
138	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 271-277.	3.3	60
139	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	0.6	59
140	Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 625-629.	1.2	58
141	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. <i>Leukemia</i> , 2015, 29, 1832-1838.	3.3	58
142	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
143	Inhibition of c-myc Expression Induced by 4-Hydroxynonenal, a Product of Lipid Peroxidation, in the HL-60 Human Leukemic Cell Line. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 553-561.	1.0	57
144	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007, 92, 101-105.	1.7	57

#	ARTICLE	IF	CITATIONS
145	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- <i>a</i> ]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6034-6055.	2.9	57
146	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
147	Human T gamma globin chain is a variant of A gamma chain (A gamma Sardinia).. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1979, 76, 3420-3424.	3.3	56
148	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
149	Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 1674-1683.	3.2	55
150	Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). <i>Blood</i> , 2014, 124, 152-152.	0.6	55
151	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. <i>American Journal of Hematology</i> , 2015, 90, E66-72.	2.0	54
152	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. <i>Blood</i> , 2006, 107, 1591-1598.	0.6	53
153	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- $\alpha$ : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774.	1.7	53
154	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. <i>Blood</i> , 2011, 118, 5697-5700.	0.6	53
155	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. <i>Haematologica</i> , 2012, 97, 907-914.	1.7	53
156	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	3.3	51
157	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	0.8	48
158	BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- $\alpha$ in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 1999, 94, 2200-2207.	0.6	47
159	An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. <i>Haematologica</i> , 2007, 92, 970-973.	1.7	47
160	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	2.0	47
161	BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. <i>American Journal of Pathology</i> , 1997, 150, 155-65.	1.9	47
162	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 3634-3644.	0.6	46

#	ARTICLE	IF	CITATIONS
163	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	6.9	45
164	Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. <i>Blood</i> , 1988, 72, 1203-1208.	0.6	43
165	Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches. <i>Cancer Research</i> , 2007, 67, 5300-5307.	0.4	43
166	The response to imatinib and interferon- $\alpha$ is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010, 95, 1415-1419.	1.7	43
167	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	3.3	43
168	NF- $\kappa$ B inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. <i>American Journal of Hematology</i> , 2006, 81, 938-945.	2.0	42
169	Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 454-459.	0.8	42
170	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. <i>Haematologica</i> , 2014, 99, 1204-1211.	1.7	42
171	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia. <i>EMBO Journal</i> , 1984, 3, 2641-5.	3.5	41
172	Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF- $\kappa$ B in AML carrying NPM1 mutations. <i>Leukemia</i> , 2008, 22, 1234-1240.	3.3	40
173	Clinical and Haematological Data in 254 Cases of Beta- $\theta$ Thalassaemia Trait in Italy. <i>British Journal of Haematology</i> , 1976, 33, 91-99.	1.2	39
174	4-Hydroxynonenal Specifically Inhibits c-myc but Does Not Affect c-fos Expressions in HL-60 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 589-593.	1.0	39
175	Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. <i>Blood</i> , 2003, 102, 773-774.	0.6	39
176	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008, 93, 1814-1821.	1.7	39
177	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. <i>Expert Review of Hematology</i> , 2010, 3, 665-673.	1.0	39
178	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	1.7	39
179	P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. <i>British Journal of Haematology</i> , 1998, 103, 1104-1108.	1.2	38
180	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , 2003, 102, 2014-2020.	0.6	38

#	ARTICLE	IF	CITATIONS
181	Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t(8;14) translocation. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 1-7.	1.5	37
182	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , 1994, 68, 3-7.	0.8	37
183	Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. <i>Leukemia</i> , 2002, 16, 1745-1751.	3.3	37
184	A New HPLC-UV Validated Method for Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Leukemic Patients. <i>Journal of Chromatographic Science</i> , 2011, 49, 753-757.	0.7	37
185	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. <i>Leukemia</i> , 2002, 16, 268-275.	3.3	36
186	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. <i>Hematological Oncology</i> , 2006, 24, 196-204.	0.8	36
187	The Role of PTEN in Myeloid Malignancies. <i>Hematology Reports</i> , 2015, 7, 6027.	0.3	36
188	Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. <i>Tissue Engineering - Part C: Methods</i> , 2017, 23, 72-85.	1.1	36
189	Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2249.	1.8	36
190	Mobilization of Cytogenetically "Normal" Blood Progenitors Cells by Intensive Conventional Chemotherapy for Chronic Myeloid and Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 9, 477-483.	0.6	35
191	Human Herpesvirus Type-8 (HHV-8) in Haematopoietic Neoplasia. <i>Leukemia and Lymphoma</i> , 1997, 24, 257-266.	0.6	35
192	Nilotinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2019, 15, 953-965.	1.1	35
193	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. <i>Leukemia</i> , 2020, 34, 2064-2073.	3.3	35
194	Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. <i>Leukemia</i> , 1993, 7, 946-53.	3.3	35
195	A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. <i>Blood</i> , 2000, 95, 96-101.	0.6	35
196	Simultaneous screening for $\beta$ -thalassaemia mutations by chemical cleavage of mismatch. <i>Genomics</i> , 1991, 11, 48-53.	1.3	34
197	A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 50-55.	2.1	34
198	Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 287-299.	1.4	34

#	ARTICLE	IF	CITATIONS
199	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. <i>British Journal of Haematology</i> , 2015, 170, 398-407.	1.2	34
200	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. <i>Blood</i> , 2013, 122, 92-92.	0.6	34
201	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. <i>Blood</i> , 1987, 69, 1058-1061.	0.6	33
202	Point mutations of the BCL-6 gene in Burkitt's lymphoma. <i>British Journal of Haematology</i> , 1997, 99, 168-170.	1.2	33
203	The tyrosine kinase receptor Met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 285-291.	3.3	33
204	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. <i>Cancer</i> , 2006, 106, 1188-1196.	2.0	33
205	5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 18.	6.9	33
206	A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. <i>The Hematology Journal</i> , 2002, 3, 315-316.	2.0	33
207	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , 1990, 76, 1819-24.	0.6	33
208	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. , 1996, 16, 21-30.		32
209	Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. <i>Cancer</i> , 2004, 101, 979-988.	2.0	32
210	The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice. <i>Haematologica</i> , 2014, 99, 1016-1021.	1.7	32
211	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
212	Analysis of Human Herpesvirus Type 8 Infection in AIDS-Related and AIDS-Unrelated Primary Central Nervous System Lymphoma. <i>Journal of Infectious Diseases</i> , 1997, 175, 1193-1197.	1.9	31
213	HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. <i>International Journal of Hematology</i> , 2009, 90, 392-396.	0.7	31
214	Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 223-229.	0.2	31
215	Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. <i>Leukemia</i> , 1992, 6, 507-12.	3.3	31
216	A new TaqI polymorphism in the p53 gene. <i>Nucleic Acids Research</i> , 1992, 20, 928-928.	6.5	30

#	ARTICLE	IF	CITATIONS
217	Rapid identification by denaturing gradient gel electrophoresis of mutations in the $\beta$ -globin gene promoters in non-deletion type HPFH. <i>British Journal of Haematology</i> , 1992, 80, 533-538.	1.2	30
218	Analysis of microsatellite instability in chronic lymphoproliferative disorders. <i>Annals of Hematology</i> , 1996, 72, 67-71.	0.8	30
219	Detection of BCL-6 rearrangements and p53 mutations in malt-lymphomas. , 1997, 56, 206-213.		30
220	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , 1993, 81, 166-76.	0.6	30
221	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. <i>Haematologica</i> , 2001, 86, 252-9.	1.7	30
222	Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 106-111.	1.5	29
223	Down-modulation of the C/EBP $\beta$ transcription factor in core binding factor acute myeloid leukemias. <i>Blood</i> , 2003, 102, 2705-2706.	0.6	29
224	JAK2V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2006, 135, 267-268.	1.2	29
225	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , 2007, 21, 1481-1487.	3.3	29
226	Bone marrow microenvironment: The guardian of leukemia stem cells. <i>World Journal of Stem Cells</i> , 2019, 11, 476-490.	1.3	29
227	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph $\phi$ -negative peripheral stem cells. <i>British Journal of Haematology</i> , 1994, 87, 867-870.	1.2	28
228	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. <i>Clinical Cancer Research</i> , 2009, 15, 1059-1063.	3.2	28
229	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014, 38, 155-160.	0.4	28
230	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. <i>Blood</i> , 2009, 114, 1129-1129.	0.6	28
231	Delineation of specific beta-thalassemia mutations in high-risk areas of Italy: a prerequisite for prenatal diagnosis. <i>Blood</i> , 1988, 71, 983-988.	0.6	27
232	First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. <i>Leukemia and Lymphoma</i> , 2018, 59, 1523-1538.	0.6	27
233	HHV $\phi$ /KSHV is Not Associated with AIDS-Related Primary Central Nervous System Lymphoma. <i>Brain Pathology</i> , 1999, 9, 199-208.	2.1	26
234	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR $\phi$ -ABL1-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2010, 24, 66-73.	3.3	26

#	ARTICLE	IF	CITATIONS
235	BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. <i>Cell Cycle</i> , 2015, 14, 973-979.	1.3	26
236	A frequent A $\alpha$ -persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with $\beta$ -thalassemia. <i>Human Genetics</i> , 1988, 79, 13-17.	1.8	25
237	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 345-350.	1.1	25
238	Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. <i>Annals of Hematology</i> , 2014, 93, 1401-12.	0.8	25
239	A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning. <i>Cancers</i> , 2020, 12, 1684.	1.7	25
240	The BCR-ABL/NF- $\kappa$ B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. <i>Oncotarget</i> , 2016, 7, 66287-66298.	0.8	25
241	Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation. <i>American Journal of Human Genetics</i> , 1991, 48, 631-5.	2.6	25
242	A benign form of thalassaemia intermedia may be determined by the interaction of triplicated $\delta$ locus and heterozygous $\beta^2$ -thalassaemia. <i>British Journal of Haematology</i> , 1987, 66, 103-107.	1.2	24
243	A newly-characterized $\delta$ -thalassaemia-1 deletion removes the entire $\delta$ -like globin gene cluster in an Italian family. <i>British Journal of Haematology</i> , 1991, 78, 529-534.	1.2	24
244	Molecular pathology of AIDS-related lymphomas. <i>Annals of Hematology</i> , 1994, 69, 281-290.	0.8	24
245	AIDS-Related Non-Hodgkin's Lymphomas: Molecular Genetics, Viral Infection and Cytokine Deregulation. <i>Acta Haematologica</i> , 1996, 95, 193-198.	0.7	24
246	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2006, 17, 495-502.	0.6	24
247	Two novel mutations in the <i>tmprss6</i> gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form. <i>British Journal of Haematology</i> , 2012, 158, 668-672.	1.2	24
248	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2014, 38, 236-242.	0.4	24
249	$\beta$ - $\delta$ : At the crossroad between oncogenic and tumor-suppressive signals. <i>Oncology Letters</i> , 2017, 13, 531-534.	0.8	24
250	ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). <i>Blood</i> , 2010, 116, 207-207.	0.6	24
251	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. <i>Blood</i> , 2013, 122, 653-653.	0.6	24
252	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24

#	ARTICLE	IF	CITATIONS
253	Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continuous clinical remission. <i>British Journal of Haematology</i> , 1995, 90, 364-368.	1.2	23
254	Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1998, 103, 143-149.	1.2	23
255	The molecular anatomy of the FIP1L1-PDGFR $\alpha$ fusion gene. <i>Leukemia</i> , 2009, 23, 271-278.	3.3	23
256	Prediction of outcomes in patients with Ph <sup>+</sup> chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. <i>Leukemia</i> , 2013, 27, 907-913.	3.3	23
257	Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2105-2113.	0.6	23
258	The choice of first-line Chronic Myelogenous Leukemia treatment. <i>Annals of Hematology</i> , 2015, 94, 123-131.	0.8	23
259	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , 2016, 16, 572.	1.1	23
260	Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. <i>Scientific Reports</i> , 2016, 6, 33432.	1.6	23
261	Bcl $\kappa$ L represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10978-10986.	1.6	23
262	Epha3 acts as proangiogenic factor in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 34298-34309.	0.8	23
263	THE HOMOZYGOUS STATE FOR THE -87 C $\hat{a}$ T $\hat{c}$ G $\hat{c}$ T $\hat{c}$ +THALASSAEMIA. <i>British Journal of Haematology</i> , 1990, 75, 132-133.	1.2	22
264	CHRONIC NEUTROPHILIC LEUKAEMIA ASSOCIATED WITH POLYCYTHEMIA VERA: PATHOGENETIC IMPLICATIONS AND THERAPEUTIC APPROACH. <i>British Journal of Haematology</i> , 1991, 78, 286-288.	1.2	22
265	Microsatellite instability in KSHV/HHV-8 positive body-cavity-based lymphoma. <i>Human Pathology</i> , 1997, 28, 748-750.	1.1	22
266	Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: Pathogenetic and histogenetic implications. <i>Human Pathology</i> , 2000, 31, 871-873.	1.1	22
267	Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 423-431.	1.8	22
268	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. <i>Leukemia</i> , 2007, 21, 1442-1450.	3.3	22
269	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	1.7	22
270	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	1.7	22



#	ARTICLE	IF	CITATIONS
271	Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. <i>Blood Cancer Journal</i> , 2018, 8, 88.	2.8	22
272	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. <i>Blood</i> , 2019, 134, 2924-2924.	0.6	22
273	The relationship between anemia, fecal stercobilinogen, erythrocyte survival, and globin synthesis in heterozygotes for beta-thalassemia. <i>Blood</i> , 1975, 46, 693-698.	0.6	21
274	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. <i>Cancer Genetics and Cytogenetics</i> , 1989, 42, 191-201.	1.0	21
275	Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 305-308.	1.2	21
276	Update on emerging treatments for chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 183-196.	1.0	21
277	<i>De novo UBE2A</i> mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. <i>Haematologica</i> , 2019, 104, 1789-1797.	1.7	21
278	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1003.	1.7	21
279	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	1.7	21
280	Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2012, 120, 1676-1676.	0.6	21
281	ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7073-7073.	0.8	21
282	Suboptimal responses in chronic myeloid leukemia. <i>Cancer</i> , 2012, 118, 1181-1191.	2.0	20
283	Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. <i>Blood</i> , 2009, 114, LBA-1-LBA-1.	0.6	20
284	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
285	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. <i>Haematologica</i> , 2003, 88, 256-9.	1.7	20
286	Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 147-153.	1.1	19
287	Haplotype distribution and molecular defects at the phenylalanine hydroxylase locus in Italy. <i>Human Genetics</i> , 1990, 86, 69-72.	1.8	19
288	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1993, 84, 265-268.	1.2	19

#	ARTICLE	IF	CITATIONS
289	BCR/ABL Transcripts and Leukemia Phenotype: An Unsolved Puzzle. <i>Leukemia and Lymphoma</i> , 1997, 26, 281-286.	0.6	19
290	The Role of Cytokines in the Pathogenesis and Management of Aids-Related Lymphomas. <i>Leukemia and Lymphoma</i> , 2000, 38, 481-488.	0.6	19
291	Oncogenic protein tyrosine kinases. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 2897-2911.	2.4	19
292	Insertions generating the 5'RUNX1/3?CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 86-91.	1.5	19
293	Morgana acts as an oncosuppressor in chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 2245-2253.	0.6	19
294	Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse. <i>Scientific Reports</i> , 2016, 6, 30725.	1.6	19
295	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 1660-1672.	2.0	19
296	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- <i>a</i> ]pyridine Scaffold: SAR of the Biphenyl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5404-5428.	2.9	19
297	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	0.6	19
298	Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 450-450.	0.6	19
299	Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.. <i>Journal of Clinical Oncology</i> , 2010, 28, 6501-6501.	0.8	19
300	Molecular Defects Associated with the Acute Phase CML. <i>Leukemia and Lymphoma</i> , 1993, 11, 25-28.	0.6	18
301	NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia. <i>PLoS ONE</i> , 2010, 5, e12855.	1.1	18
302	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1650-1657.	1.6	18
303	Prospects for achieving treatment-free remission in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 318-327.	1.2	18
304	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. <i>Blood</i> , 2012, 120, 1675-1675.	0.6	18
305	Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2015, 126, 2781-2781.	0.6	18
306	3' c-myc rearrangement in a human leukemic T-cell line. <i>Cancer Research</i> , 1986, 46, 1413-7.	0.4	18

#	ARTICLE	IF	CITATIONS
307	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C-T nonsense mutation at codon 39.. EMBO Journal, 1984, 3, 785-787.	3.5	17
308	Selective overshoot of ph&hyphen;negative blood hemopoietic cells after intensive idarubicin&hyphen;containing regimen and their repopulating capacity after reinfusion. Stem Cells, 1993, 11, 67-72.	1.4	17
309	Iron Chelation Therapy in Myelodysplastic Syndromes. Advances in Hematology, 2010, 2010, 1-8.	0.6	17
310	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leukemia Research, 2013, 37, 520-530.	0.4	17
311	BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia. PLoS ONE, 2014, 9, e110682.	1.1	17
312	Prognostic significance of The Wilmsâ€™ Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. Leukemia Research, 2018, 67, 6-11.	0.4	17
313	Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts. Journal of Clinical Medicine, 2020, 9, 1457.	1.0	17
314	Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.. Blood, 2010, 116, 3430-3430.	0.6	17
315	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	0.6	17
316	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: Correlation with chemotherapy intensity and clinical outcome. Leukemia Research, 1996, 20, 441-443.	0.4	16
317	Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia. Journal of Oncology, 2009, 2009, 1-2.	0.6	16
318	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European Journal of Cancer, 2011, 47, 814-818.	1.3	16
319	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 2013, 13, 173.	1.1	16
320	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology, 2017, 96, 1303-1313.	0.8	16
321	Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patientâ€™Physician Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 375-379.	0.2	16
322	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 644-646.	1.2	16
323	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes Î²BÎ± mediated p53 nuclear exclusion. Oncotarget, 2015, 6, 25217-25225.	0.8	16
324	Polymorphisms of human Î³-globin genes in Mediterranean populations. Nature, 1979, 282, 316-318.	13.7	15

#	ARTICLE	IF	CITATIONS
325	Electrophoretic separation of A $\beta$ and G $\beta$ human globin chains in nonidet P-40. Clinica Chimica Acta, 1979, 99, 7-11.	0.5	15
326	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes and Cancer, 1997, 19, 250-255.	1.5	15
327	<I>WT1</I> Overexpression in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2006, 125, 199-212.		15
328	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. Haematologica, 2007, 92, 1721-1722.	1.7	15
329	A comparative study of myocardial molecular phenotypes of two tfr2 $\beta$ null mice: Role in ischemia/reperfusion. BioFactors, 2015, 41, 360-371.	2.6	15
330	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica, 2017, 102, 1530-1536.	1.7	15
331	ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. British Journal of Haematology, 1990, 76, 39-44.	1.2	14
332	p53 Mutation in a Case of Blastic Transformation of Follicular Lymphoma with Double bcl-2 Rearrangement (MBR and VCR). Leukemia and Lymphoma, 1998, 29, 595-605.	0.6	14
333	Lack of SH3 domain does not imply a more severe clinical course in Ph+ chronic myeloid leukemia patients. Blood, 2000, 95, 4019-4020.	0.6	14
334	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. European Journal of Haematology, 2011, 87, 409-418.	1.1	14
335	CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. Stem Cell Investigation, 2017, 4, 57-57.	1.3	14
336	Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. International Journal of Molecular Sciences, 2020, 21, 7674.	1.8	14
337	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	0.6	14
338	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget, 2017, 8, 88021-88033.	0.8	14
339	A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica, 1999, 84, 707-15.	1.7	14
340	Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. British Journal of Haematology, 1997, 98, 726-732.	1.2	13
341	BCL-6 in Aids-Related Lymphomas: Pathogenetic and Histogenetic Implications. Leukemia and Lymphoma, 1998, 31, 39-46.	0.6	13
342	First-line Therapy for Chronic Myeloid Leukemia: New Horizons and an Update. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 169-176.	0.2	13

#	ARTICLE	IF	CITATIONS
343	Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?. <i>Seminars in Hematology</i> , 2010, 47, 319-326.	1.8	13
344	What challenges remain in chronic myeloid leukemia research?. <i>Haematologica</i> , 2013, 98, 1168-1172.	1.7	13
345	Milestones and Monitoring. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 167-172.	1.2	13
346	Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S96-S100.	0.2	13
347	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008, 112, 185-185.	0.6	13
348	Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. <i>Medical and Pediatric Oncology</i> , 1991, 19, 240-245.	1.0	12
349	Molecular Pathways in Low Grade B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 107-113.	0.6	12
350	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon- $\alpha$ -based therapy. <i>Bone Marrow Transplantation</i> , 2000, 25, 729-736.	1.3	12
351	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. <i>Seminars in Hematology</i> , 2003, 40, 37-41.	1.8	12
352	Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. <i>Blood</i> , 2005, 106, 1887-1888.	0.6	12
353	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. <i>Neurological Sciences</i> , 2008, 29, 185-187.	0.9	12
354	New therapeutic approaches and prognostic factors in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 625-628.	0.6	12
355	CML: a model for targeted therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 285-294.	0.7	12
356	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 504-507.	0.4	12
357	Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 410-412.	1.0	12
358	<scp>HAUSP</scp> compartmentalization in chronic myeloid leukemia. <i>European Journal of Haematology</i> , 2015, 94, 318-321.	1.1	12
359	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 767-773.	1.1	12
360	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010, 116, 2291-2291.	0.6	12

#	ARTICLE	IF	CITATIONS
361	Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. <i>Blood</i> , 2011, 118, 2767-2767.	0.6	12
362	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , 2012, 120, 1686-1686.	0.6	12
363	Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7124-TPS7124.	0.8	12
364	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. <i>Leukemia</i> , 1999, 13, 1463-1464.	3.3	11
365	Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2013, 130, 268-278.	0.7	11
366	Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias. <i>Advances in Hematology</i> , 2015, 2015, 1-6.	0.6	11
367	Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2752-2754.	0.6	11
368	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , 2021, 11, 642005.	1.3	11
369	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2009, 114, 3292-3292.	0.6	11
370	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. <i>Blood</i> , 2011, 118, 452-452.	0.6	11
371	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. <i>Blood</i> , 2016, 128, 3094-3094.	0.6	11
372	Detection of Ph1-positive acute lymphoblastic leukaemia by PCR. <i>Lancet</i> , The, 1991, 338, 958.	6.3	10
373	Occurrence of the same chromosome abnormalities in Ph+ and Ph? cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?. <i>British Journal of Haematology</i> , 2006, 135, 265-266.	1.2	10
374	CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF- $\kappa$ B subunit p65 at Ser536. <i>Leukemia</i> , 2007, 21, 1305-1306.	3.3	10
375	Germ-line configuration of the T-cell receptor beta-chain gene in B-cell chronic lymphoproliferative disorders which co-express T-cell antigens. <i>European Journal of Haematology</i> , 1987, 39, 412-417.	1.1	10
376	Mechanisms of p53 Functional De-Regulation: Role of the I $\kappa$ B- $\beta$ /p53 Complex. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1997.	1.8	10
377	The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. <i>BMC Cancer</i> , 2016, 16, 314.	1.1	10
378	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	2.0	10

#	ARTICLE	IF	CITATIONS
379	Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 271.	1.0	10
380	Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 35.	1.0	10
381	Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib. <i>Blood</i> , 2010, 116, 358-358.	0.6	10
382	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	0.6	10
383	Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6512-6512.	0.8	10
384	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. <i>Oncoscience</i> , 2015, 2, 382-394.	0.9	10
385	Molecular Pathogenesis of B-Cell Chronic Lymphocytic Leukemia: Analysis of 13q14 Chromosomal Deletions. <i>Current Topics in Microbiology and Immunology</i> , 2000, 252, 275-284.	0.7	10
386	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	1.3	10
387	Polymorphism of human fetal haemoglobin studied by isoelectric focusing. <i>FEBS Letters</i> , 1980, 115, 68-70.	1.3	9
388	Fetal haemoglobin synthesis following fetal liver transplantation in man. <i>British Journal of Haematology</i> , 1983, 55, 609-614.	1.2	9
389	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. , 1996, 15, 48-53.		9
390	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 2000, 27, 177-182.		9
391	Myelodysplastic Syndromes. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 400-408.	1.8	9
392	Imatinib mesylate in the treatment of c-kit <sup>+</sup> positive acute myeloid leukemia: is this the real target?. <i>Blood</i> , 2005, 105, 904-905.	0.6	9
393	Interferon- $\gamma$ plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. <i>European Journal of Haematology</i> , 1995, 55, 184-188.	1.1	9
394	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	0.6	9
395	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1151-1158.	0.6	9
396	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. <i>Blood Reviews</i> , 2017, 31, 139-150.	2.8	9

#	ARTICLE	IF	CITATIONS
397	Recent advances in the genomics and therapy of BCR/ABL1 -positive and -negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 67, 67-74.	0.4	9
398	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6509-6509.	0.8	9
399	Variable but consistent pattern of Meningioma 1 gene ( <i>MN1</i> ) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. <i>Oncotarget</i> , 2016, 7, 74082-74096.	0.8	9
400	Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?. <i>Cancers</i> , 2021, 13, 5470.	1.7	9
401	Meiotic recombination in the beta globin gene cluster causing an error in prenatal diagnosis of beta thalassaemia.. <i>Journal of Medical Genetics</i> , 1988, 25, 307-310.	1.5	8
402	Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor. <i>Stem Cells</i> , 1994, 12, 521-526.	1.4	8
403	Translucin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). <i>Leukemia</i> , 1999, 13, 1635-1637.	3.3	8
404	Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. <i>Blood</i> , 2004, 103, 2428-2429.	0.6	8
405	From Genes to Therapy: The Case of Philadelphia Chromosome-Positive Leukemias. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 306-312.	1.8	8
406	Genetic Abnormalities as Targets for Molecular Therapies in Myelodysplastic Syndromes. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 411-423.	1.8	8
407	Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. <i>British Journal of Haematology</i> , 2011, 152, 108-110.	1.2	8
408	Practical Monitoring of Chronic Myelogenous Leukemia: When to Change Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 121-129.	2.3	8
409	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. <i>Biomarker Research</i> , 2015, 3, 15.	2.8	8
410	Ponatinib for chronic myeloid leukaemia: future perspectives. <i>Lancet Oncology</i> , The, 2016, 17, 546-547.	5.1	8
411	The Wilms™ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. <i>Cancer Medicine</i> , 2016, 5, 1650-1653.	1.3	8
412	Clinical significance of <i>TFR2</i> and <i>EPOR</i> expression in bone marrow cells in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2017, 176, 491-495.	1.2	8
413	Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. <i>Bioelectrochemistry</i> , 2018, 122, 84-92.	2.4	8
414	Present results and future perspectives in optimizing chronic myeloid leukemia therapy. <i>Haematologica</i> , 2018, 103, 928-930.	1.7	8



#	ARTICLE	IF	CITATIONS
415	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019, 37, 240-252.	0.8	8
416	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	0.6	8
417	Glivec and CML: a lucky date. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2004, 18, 246-51.	0.7	8
418	Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. <i>Leukemia Research</i> , 1982, 6, 155-163.	0.4	7
419	Molecular characterization of Ph <sup>+</sup> hybrid acute leukemia. <i>Leukemia Research</i> , 1989, 13, 1061-1067.	0.4	7
420	IMMUNOGLOBULIN GENE REARRANGEMENTS IN HUMAN MULTIPLE MYELOMA. <i>British Journal of Haematology</i> , 1989, 73, 425-425.	1.2	7
421	Hematopoietic growth factors in autologous transplantation. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1998, 10, 299-308.	0.7	7
422	BCR/ABL rearrangement and leukemia phenotype. <i>Leukemia</i> , 1999, 13, S96-S96.	3.3	7
423	MLL-AF6 fusion resulting from a new three-way translocation t(6;11;7) in a patient with acute myeloid leukemia. <i>Leukemia</i> , 2001, 15, 1674-1676.	3.3	7
424	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. <i>Cancer Letters</i> , 2009, 276, 61-67.	3.2	7
425	Chronic Myeloid Leukemia: State of the Art in 2012. <i>Current Oncology Reports</i> , 2012, 14, 379-386.	1.8	7
426	Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	7
427	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. <i>Oncotarget</i> , 2017, 8, 6399-6405.	0.8	7
428	A new BCR-ABL1 <i>Drosophila</i> model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 717-728.	1.7	7
429	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3752.	1.0	7
430	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011, 118, 2756-2756.	0.6	7
431	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. <i>Blood</i> , 2015, 126, 4040-4040.	0.6	7
432	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. <i>Blood</i> , 1987, 69, 1058-61.	0.6	7

#	ARTICLE	IF	CITATIONS
433	The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2000, 110, 493-6.	1.2	7
434	Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells. <i>Journal of Clinical Medicine</i> , 2021, 10, 5805.	1.0	7
435	Soluble factor(s) released by the PF-382 T-cell line enhances the stimulatory effect of monocytes on the BFU-E growth. <i>Journal of Cellular Physiology</i> , 1988, 135, 127-132.	2.0	6
436	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1991, 52, 63-69.	1.0	6
437	Involvement of the bcl-6 gene in AIDS-related lymphomas. <i>Annals of Oncology</i> , 1997, 8, S105-S108.	0.6	6
438	Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene. <i>Cancer Genetics and Cytogenetics</i> , 2002, 132, 46-50.	1.0	6
439	Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 2002, 133, 98-101.	1.0	6
440	Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14). <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 51-56.	1.0	6
441	Repeated PCR in CML during IFN $\alpha$ ± therapy. <i>European Journal of Haematology</i> , 1994, 52, 152-155.	1.1	6
442	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. <i>Blood</i> , 2009, , .	0.6	6
443	BCR/ABL1 Fusion Transcripts Generated from Alternative Splicing: Implications for Future Targeted Therapies in Ph+ Leukaemias. <i>Current Molecular Medicine</i> , 2012, 12, 547-565.	0.6	6
444	RBC-transfusion guidelines update. <i>Leukemia Research</i> , 2012, 36, 659-660.	0.4	6
445	Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S272-S275.	0.2	6
446	Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 797-801.	1.7	6
447	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 1938-1948.	0.6	6
448	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
449	Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?. <i>Haematologica</i> , 2019, 104, 862-864.	1.7	6
450	Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. <i>Cancers</i> , 2020, 12, 3287.	1.7	6

#	ARTICLE	IF	CITATIONS
451	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
452	Analysis of microsatellite instability in chronic lymphoproliferative disorders. <i>Annals of Hematology</i> , 1996, 72, 67-71.	0.8	6
453	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018, 132, 1750-1750.	0.6	6
454	Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. <i>Haematologica</i> , 2002, 87, 688-94; discussion 694.	1.7	6
455	Γ <sup>2</sup> and Α <sup>2</sup> globin chain synthesis in bone marrow and peripheral blood of β <sup>0</sup> -thalassaemia homozygotes. <i>British Journal of Haematology</i> , 1982, 52, 225-231.	1.2	5
456	Molecular characterization of hereditary persistence of fetal hemoglobin in a patient from Cuba [letter]. <i>Blood</i> , 1990, 76, 1262-1263.	0.6	5
457	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. <i>Leukemia</i> , 2004, 18, 1824-1830.	3.3	5
458	WT1 overexpression: A clinically useful marker in acute and chronic myeloid leukemias. <i>Hematology</i> , 2005, 10, 76-78.	0.7	5
459	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189.	2.0	5
460	BCR-ABL1 mutation and ponatinib resistance. <i>Blood</i> , 2016, 127, 666-667.	0.6	5
461	Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3330-3332.	0.6	5
462	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e101-e105.	1.2	5
463	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. <i>Haematologica</i> , 2021, 106, 1787-1793.	1.7	5
464	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRΑ Rearrangement Can Be Effectively Treated with Imatinib.. <i>Blood</i> , 2004, 104, 1504-1504.	0.6	5
465	Sequential Therapy with IMiD's in Relapsed-Refractory Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 2888-2888.	0.6	5
466	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study.. <i>Blood</i> , 2011, 118, 3770-3770.	0.6	5
467	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7052-7052.	0.8	5
468	Genetic studies on some Nepalese populations. <i>Journal of Human Evolution</i> , 1979, 8, 385-397.	1.3	4

#	ARTICLE	IF	CITATIONS
469	Î³ Chain Composition in Five Italian Newborns Heterozygous for Hb F Malta <sup>G</sup>Î³<sup>117 His â†’ Arg</sup>. British Journal of Haematology, 1980, 44, 93-99.	1.2	4
470	FETAL DIAGNOSIS OF Î²-THALASSAEMIA BY DNA ANALYSIS IN ITALY. Lancet, The, 1986, 327, 390.	6.3	4
471	Duplication of Ph and of 9q+ chromosomes during the blastic transformation of a CML case. Cancer Genetics and Cytogenetics, 1987, 29, 57-63.	1.0	4
472	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. Cancer Genetics and Cytogenetics, 1991, 55, 235-241.	1.0	4
473	Identification of a Novel Mutation in the L Ferritin Iron-Responsive Element Causing Hereditary Hyperferritinemia-Cataract Syndrome. Acta Haematologica, 2009, 122, 223-225.	0.7	4
474	Immunologic Evaluation of Peptides Derived From BCR/ABL-Out-of-Frame Fusion Protein in HLA A2.1 Transgenic Mice. Journal of Immunotherapy, 2012, 35, 321-328.	1.2	4
475	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617Fmutation in Myeloproliferative Neoplasms. BMC Cancer, 2013, 13, 348.	1.1	4
476	The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia. Oncology Letters, 2016, 12, 3123-3126.	0.8	4
477	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2016, 57, 1517-1526.	0.6	4
478	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. Journal of Clinical Medicine, 2020, 9, 1670.	1.0	4
479	Point: Is there a best duration of deep molecular response to achieve therapyâ€free remission in chronic myeloid leukaemia?. British Journal of Haematology, 2021, 192, 22-23.	1.2	4
480	The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner. Cancers, 2021, 13, 341.	1.7	4
481	Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern. Blood, 2018, 132, 788-788.	0.6	4
482	Molecular Heterogeneity of the FIP1L1-PDGFR $\alpha$ Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. Blood, 2004, 104, 2428-2428.	0.6	4
483	The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program. Blood, 2014, 124, 4534-4534.	0.6	4
484	Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.. Journal of Clinical Oncology, 2010, 28, 6512-6512.	0.8	4
485	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a Câ†’T nonsense mutation at codon 39. EMBO Journal, 1984, 3, 785-7.	3.5	4
486	The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation. Journal of Clinical Medicine, 2022, 11, 324.	1.0	4

#	ARTICLE	IF	CITATIONS
487	Composition of the $\alpha$ -Chains of Human Fetal Hemoglobin at Birth and during Intrauterine Life. <i>Acta Haematologica</i> , 1979, 62, 45-50.	0.7	3
488	Haplotype distribution and molecular defects of PKU in Italy. <i>Journal of Inherited Metabolic Disease</i> , 1990, 13, 292-294.	1.7	3
489	Molecular and cytogenetic studies of a patient with philadelphia-negative, BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). <i>Genes Chromosomes and Cancer</i> , 1990, 1, 284-288.	1.5	3
490	Chromosome abnormalities involving heterochromatic regions in monocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1990, 46, 99-106.	1.0	3
491	Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia line. <i>Carcinogenesis</i> , 1992, 13, 883-885.	1.3	3
492	Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation.. <i>Journal of Medical Genetics</i> , 1993, 30, 228-231.	1.5	3
493	Isochromosome 6p and deletion of 6q characterize two related cytogenetic clones in a patient with immunoblastic lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1995, 81, 179-181.	1.0	3
494	Detection of Humoral Immune Responses against WT1 Antigen in Patients Affected by Different Hematological Malignancies. <i>Acta Haematologica</i> , 2008, 120, 47-50.	0.7	3
495	Isolated molecular relapse in FIP1L1-PDGFR $\alpha$ hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1161-1163.	1.1	3
496	Emerging drugs for chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 175-184.	1.0	3
497	Characterization of a Monoclonal Antibody Specific for Novel Bcr/Abl Out-of-Frame Fusion Proteins. <i>Hybridoma</i> , 2011, 30, 261-269.	0.5	3
498	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post $\alpha$ Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1852-1855.	2.0	3
499	Chronic myeloid leukemia: room for improvement?. <i>Haematologica</i> , 2017, 102, 1131-1133.	1.7	3
500	Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. <i>British Journal of Haematology</i> , 2018, 180, 895-898.	1.2	3
501	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2018, 36, 740-748.	0.8	3
502	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , 2020, 38, 654-664.	0.8	3
503	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	3.3	3
504	The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL. , 0, , .		3

#	ARTICLE	IF	CITATIONS
505	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	0.6	3
506	Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. <i>Blood</i> , 2019, 134, 2932-2932.	0.6	3
507	Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom. <i>Blood</i> , 2020, 136, 7-8.	0.6	3
508	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2192-2192.	0.6	3
509	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. <i>Blood</i> , 2012, 120, 1702-1702.	0.6	3
510	Association of lymphocytosis following treatment with dasatinib with response and outcome.. <i>Journal of Clinical Oncology</i> , 2010, 28, 6553-6553.	0.8	3
511	New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. <i>Oncoscience</i> , 2015, 2, 880-891.	0.9	3
512	Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia. <i>Current Drug Targets</i> , 2017, 18, 389-395.	1.0	3
513	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7054-7054.	0.8	3
514	High Hb F levels in a Sardinian family: a genetic defect intermediate between HPFH Greek type and delta beta-thalassemia?. <i>Haematologica</i> , 1982, 67, 499-507.	1.7	3
515	Biosynthetic Studies and $\alpha$ -Chain Composition in the Greek Type of Hereditary Persistence of Fetal Hemoglobin and in Its Association with $\beta$ -Thalassaemia. <i>Acta Haematologica</i> , 1979, 61, 272-277.	0.7	2
516	A Novel Type of c-myc Translocation in a T Lymphoma Cell Line. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 338-342.	1.8	2
517	CYTOGENETIC AND MOLECULAR ANALYSES IN PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA. <i>British Journal of Haematology</i> , 1988, 69, 424-426.	1.2	2
518	MOLECULAR EVIDENCE OF TRANSIENT COMPLETE REMISSION AFTER AUTOGRAFTING IN Ph-/BCR REARRANGED CHRONIC MYELOGENOUS LEUKAEMIA. <i>British Journal of Haematology</i> , 1989, 72, 285-286.	1.2	2
519	Recent advances in diagnosis of hemoglobinopathies. <i>Critical Reviews in Oncology/Hematology</i> , 1993, 14, 89-105.	2.0	2
520	Recommendations for the Molecular Diagnosis of Familial Adenomatous Polyposis. <i>Tumori</i> , 1997, 83, 795-799.	0.6	2
521	Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Acta Haematologica</i> , 2006, 116, 70-71.	0.7	2
522	A young man with persistent eosinophilia. <i>Internal and Emergency Medicine</i> , 2007, 2, 107-112.	1.0	2

#	ARTICLE	IF	CITATIONS
523	Thalidomide-induced partial stable remission in a case of refractory progressive B Cell Chronic Lymphoid Leukemia. <i>Leukemia Research</i> , 2008, 32, 506-507.	0.4	2
524	Herpetic leg paralysis and abdominal ileus in a patient with idiopathic myelofibrosis. <i>Internal and Emergency Medicine</i> , 2009, 4, 65-66.	1.0	2
525	Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?. <i>HemaSphere</i> , 2019, 3, e283.	1.2	2
526	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	1.0	2
527	Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation. <i>Blood</i> , 2010, 116, 2297-2297.	0.6	2
528	Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party. <i>Journal of Clinical Oncology</i> , 2008, 26, 7054-7054.	0.8	2
529	Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms. <i>Journal of Clinical Medicine</i> , 2022, 11, 1267.	1.0	2
530	Human gamma interferon modifies C-myc expression and growth pattern of U937 cell line but not of its subclone 1937. <i>Cell Biology International Reports</i> , 1986, 10, 467.	0.7	1
531	Multilineage cell involvement in Ph1-negative, bcr-negative chronic myeloid leukemia. <i>Leukemia Research</i> , 1988, 12, 637-645.	0.4	1
532	EFFECT OF IFN± THERAPY ON SECONDARY Ph1-POSITIVE CLONES. <i>British Journal of Haematology</i> , 1992, 81, 451-453.	1.2	1
533	Minimal residual disease in B-lymphoproliferative disorders by PCR detection of immunoglobulin heavy chain gene recombination. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 541-547.	0.6	1
534	Renal Hodgkin's disease. <i>British Journal of Haematology</i> , 2002, 116, 732-732.	1.2	1
535	Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1564-1565.	0.6	1
536	P087 Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients. <i>Leukemia Research</i> , 2009, 33, S108-S109.	0.4	1
537	Second-generation TKIs: which and when?. <i>Leukemia Supplements</i> , 2012, 1, S40-S42.	0.1	1
538	The Treatment of Chronic Myeloid Leukemia. , 2013, , .		1
539	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	0.6	1
540	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. <i>Blood</i> , 2004, 104, 1507-1507.	0.6	1

#	ARTICLE	IF	CITATIONS
541	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005, 106, 1096-1096.	0.6	1
542	The Oncogenic Kinase Bcr-Abl Directly Regulates Splicing of BclX through a Quaternary Complex Coordinated by Nck-Beta and Sam-68 Adapter Proteins.. <i>Blood</i> , 2009, 114, 2171-2171.	0.6	1
543	Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7055-7055.	0.8	1
544	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012, 120, 4903-4903.	0.6	1
545	A gamma and G gamma globin chain synthesis in BFU-E colonies from adult, newborn, and fetal subjects and from thalassemic patients. <i>Translational Research</i> , 1980, 96, 790-5.	2.4	1
546	The biology of CML supports second-generation TKIs as frontline treatment. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 302-307.	0.3	1
547	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
548	Analysis of the $\alpha$ Chains in a Homozygote for HPFH Negro Type and in Three Related Heterozygotes. <i>Acta Haematologica</i> , 1980, 63, 146-150.	0.7	0
549	Heterogeneity of $\alpha$ , $\beta$ -Thalassemia and Hereditary Persistence of Hb F in the Mediterranean Area. <i>Annals of the New York Academy of Sciences</i> , 1985, 445, 170-176.	1.8	0
550	Translocation of the c-myc oncogene $3\alpha$ to the immunoglobulin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma. <i>Cell Biology International Reports</i> , 1986, 10, 148-148.	0.7	0
551	Cloning of a c-myc gene rearranged at the $3\alpha$ derived from a human leukemic T cell line*. <i>Cell Biology International Reports</i> , 1986, 10, 198-198.	0.7	0
552	Significance of the Philadelphia Chromosome in Acute Leukemias: Variable Correlation with Rearrangements Involving the c-Abl and Bcr Genes. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 270-276.	1.8	0
553	7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. <i>Cytotechnology</i> , 1987, 1, 37-40.	0.7	0
554	Immunoglobulin DNA Analysis as a Marker of Clonality in the Follow-up of Patients with Hairy Cell Leukemia Treated with Alpha-Interferon. <i>Leukemia and Lymphoma</i> , 1990, 2, 103-110.	0.6	0
555	Biological Determinants of Long-Term Survival in Chronic Myelogenous Leukemia Patients Treated with Conventional Chemotherapy. <i>Acta Haematologica</i> , 1997, 97, 187-188.	0.7	0
556	Novel type of BCR $\alpha$ -ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. <i>British Journal of Haematology</i> , 2000, 111, 644-646.	1.2	0
557	Reply to Martinelli et al. <i>Leukemia</i> , 2003, 17, 651-652.	3.3	0
558	Prognostic Significance of Molecular Follow-up by Qualitative and Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction in TEL/AML1 $\alpha$ -Positive Childhood Acute Lymphoblastic Leukemia. <i>Clinical Leukemia</i> , 2007, 1, 298-303.	0.2	0



#	ARTICLE	IF	CITATIONS
559	Molecular monitoring in patients with chronic myelogenous leukemia. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 65-71.	1.2	0
560	P050 Deferasirox is the only iron chelator inducing NF- $\kappa$ B inhibition in myelodysplastic patients and in leukemic cell lines and acts independently from reactive oxygen species reduction. <i>Leukemia Research</i> , 2009, 33, S87-S88.	0.4	0
561	Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. <i>Leukemia</i> , 2010, , .	3.3	0
562	Development of cellular and humoral response against <sc>WT</sc> 1 protein vaccination in mice. <i>American Journal of Hematology</i> , 2015, 90, E193-4.	2.0	0
563	The Choice of First-Line Chronic Myelogenous Leukemia Treatment. <i>Hematologic Malignancies</i> , 2016, , 41-54.	0.2	0
564	Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. <i>British Journal of Haematology</i> , 2016, 173, 749-753.	1.2	0
565	Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2017, 36, 149-156.	0.8	0
566	Chronic Myeloproliferative Neoplasms: Some Remaining Challenges. <i>HemaSphere</i> , 2018, 2, e147.	1.2	0
567	Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2020, 99, 891-893.	0.8	0
568	Imatinib: The First-Line CML Therapy. <i>Hematologic Malignancies</i> , 2021, , 49-59.	0.2	0
569	Imatinib in the Treatment of CML Patients $\geq$ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2004, 104, 2935-2935.	0.6	0
570	Heterogeneous Chromosomal Mechanisms Generating the 5 $\times$ RUNX1/3 $\times$ CBFA2T1 Gene in Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 4272-4272.	0.6	0
571	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005, 106, 1100-1100.	0.6	0
572	JAK2V617F Mutation in Leukaemic Transformation of Philadelphia Negative Chronic Myeloproliferative Disorders.. <i>Blood</i> , 2006, 108, 3605-3605.	0.6	0
573	Bcr-Abl and Signal Transduction. , 2007, , 15-35.		0
574	Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.. <i>Blood</i> , 2007, 110, 1956-1956.	0.6	0
575	SIRT1 Activator 3 Potently Induces Apoptosis in Multiple Myeloma Cell Lines and in Primary Human Multiple Myeloma Cells.. <i>Blood</i> , 2009, 114, 3845-3845.	0.6	0
576	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. <i>Blood</i> , 2010, 116, 2281-2281.	0.6	0

#	ARTICLE	IF	CITATIONS
577	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
578	Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.. Blood, 2012, 120, 2500-2500.	0.6	0
579	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. Blood, 2012, 120, 1690-1690.	0.6	0
580	Î²-Thalassemic Syndromes As a Model for the Study of the Molecular Basis of Human Inherited Disease. , 1987, , 283-293.		0
581	GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. Blood, 1998, 91, 2334-2340.	0.6	0
582	Recommendations for the Management of CML in the Era of Second-Generation TKIs. , 2016, , 131-145.		0
583	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Seminars in Hematology, 2003, 40, 37-41.	1.8	0
584	The best frontline therapy for CML: imatinib?. Clinical Advances in Hematology and Oncology, 2010, 8, 240-2.	0.3	0
585	Prof. Michele Baccharani. August 16, 1942 to December 20, 2021: a gifted life in haematology. Leukemia, 2022, 36, 1199-1200.	3.3	0
586	Prof. Michele Baccharani, August 16, 1942 to December 20, 2021: a gifted life in haematology. Bone Marrow Transplantation, 2022, , .	1.3	0